Conference Coverage

Diabetic neuropathic pain linked to brain bioenergic anomalies

Publish date: October 19, 2020

 

FROM EASD 2020

SOURCE: Sloan S et al. EASD 2020, oral presentation 181.

Pages

Recommended Reading

British protocol allows insulin-treated pilots to fly safely
MDedge Endocrinology
Dapagliflozin’s CKD performance sends heart failure messages
MDedge Endocrinology
Time to screen for liver disease in type 2 diabetes?
MDedge Endocrinology
PPIs associated with diabetes risk, but questions remain
MDedge Endocrinology
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan
MDedge Endocrinology
Empagliflozin cut PA pressures in heart failure patients
MDedge Endocrinology
T2D treatments create tension between glycemic and cardiovascular goals
MDedge Endocrinology
Entresto halves renal events in preserved EF heart failure patients
MDedge Endocrinology
Substance in tears could be used for diabetes monitoring
MDedge Endocrinology
Recall widens for diabetes drug metformin
MDedge Endocrinology